SCHEMBL13520

SCHEMBL13520

NC(=O)CCCCCC1CCCCC1

nearest known ligand 0.61

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 3/20 0.57
KDM5A P29375 3/20 0.54
PHF8 Q9UPP1 3/20 0.54
KDM2A Q9Y2K7 3/20 0.54
KDM4C Q9H3R0 2/20 0.54
KDM4A O75164 1/20 0.54
NAAA Q02083 2/20 0.50
KMT2A Q03164 2/20 0.46
TARDBP Q13148 1/20 0.46
CYP1A2 P05177 1/20 0.45
EPHX1 P07099 1/20 0.45
MEN1 O00255 1/20 0.44
USP2 O75604 1/20 0.44
CYP3A4 P08684 1/20 0.44
ALOX15 P16050 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
HPGD P15428 1/20 0.44
GLA P06280 1/20 0.43
ALOX5 P09917 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25708125 1.00 SIGMAR1 (0.57) SIGMAR1KDM5APHF8KDM2AKDM4C
SCHEMBL20408333 1.00 SIGMAR1 (0.57) SIGMAR1KDM5APHF8KDM2AKDM4C
SCHEMBL8860844 1.00 SIGMAR1 (0.57) SIGMAR1KDM5APHF8KDM2AKDM4C
SCHEMBL9718136 1.00 SIGMAR1 (0.57) SIGMAR1KDM5APHF8KDM2AKDM4C
SCHEMBL11010082 1.00 SIGMAR1 (0.57) SIGMAR1KDM5APHF8KDM2AKDM4C
SCHEMBL24095875 0.98 SIGMAR1 (0.54) SIGMAR1KDM5APHF8KDM2AKDM4C
SCHEMBL931403 0.98 SIGMAR1 (0.54) SIGMAR1KDM5APHF8KDM2AKDM4C
SCHEMBL9203 0.98 SIGMAR1 (0.54) SIGMAR1KDM5APHF8KDM2AKDM4C
SCHEMBL4537554 0.98 SIGMAR1 (0.54) SIGMAR1KDM5APHF8KDM2AKDM4C
SCHEMBL4677733 0.96 KDM5A (0.50) SIGMAR1KDM5APHF8KDM2AKDM4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0497835-A1 METHOD FOR TREATING HIV AND OTHER RETROVIRUSES AND COMPOUNDS USEFUL THEREFOR THE UPJOHN COMPANY (US) 1992-08-12 EP claimed
WO-1991006561-A1 METHOD FOR TREATING HIV AND OTHER RETROVIRUSES AND COMPOUNDS USEFUL THEREFOR THE UPJOHN COMPANY (US) 1991-05-16 WO claimed
US-20230348369-A1 NAMPT MODULATORS CYTOKINETICS, INC. 2023-11-02 US disclosed
US-9296698-B2 Amino heteroaryl compounds as beta-secretase modulators and methods of use AMGEN INC. (US) 2016-03-29 US disclosed
EP-2968211-A1 PHENYL ALKYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING EPILEPSY OR EPILEPSY-RELATED SYNDROME Bio-Pharm Solutions Co., Ltd. (KR) 2016-01-20 EP disclosed
EP-2797881-A1 Phenyl alkyl carbamate derivative compound and pharmaceutical composition containing the same Bio-Pharm Solutions Co., Ltd. (KR) 2014-11-05 EP disclosed
WO-2014142519-A1 PHENYL ALKYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING EPILEPSY OR EPILEPSY-RELATED SYNDROME BIO-PHARM SOLUTIONS CO., LTD. (KR) 2014-09-18 WO disclosed
WO-2013100566-A1 Phenyl alkyl carbamate derivative compound and pharmaceutical composition containing the same BIO-PHARM SOLUTIONS CO., LTD. (KR) 2013-07-04 WO disclosed
US-20120329830-A1 Amino Heteroaryl Compounds as Beta-Secretase Modulators and Methods of Use AMGEN INC. (US) 2012-12-27 US disclosed
EP-2504315-A1 AMINO HETEROARYL COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE Amgen Inc. (US) 2012-10-03 EP disclosed
WO-2011063233-A1 AMINO HETEROARYL COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE AMGEN INC. (US) 2011-05-26 WO disclosed
WO-2011000945-A9 AMINOALKAMIDES FOR USE IN THE TREATMENT OF INFLAMMATORY, DEGENERATIVE OR DEMYELINATING DISEASES OF THE CNS NENSIUS RESEARCH A/S (DK) 2011-04-07 WO disclosed
WO-2011000945-A2 AMINOALKAMIDES FOR USE IN THE TREATMENT OF INFLAMMATORY, DEGENERATIVE OR DEMYELINATING DISEASES OF THE CNS NENSIUS RESEARCH A/S (DK) 2011-01-06 WO disclosed
US-5703129-A 5-amino-6-cyclohexyl-4-hydroxy-hexanamide derivatives as inhibitors of β-amyloid protein production BRISTOL-MYERS SQUIBB COMPANY (US) 1997-12-30 US disclosed
EP-0778266-A1 5-Amino-6-cyclohexyl-4-hydroxy-hexanamide derivatives as inhibitors of beta-amyloid protein production BRISTOL-MYERS SQUIBB COMPANY (US) 1997-06-11 EP disclosed
EP-0578745-A1 PHOSPHORUS CONTAINING COMPOUNDS AS INHIBITORS OF RETROVIRUSES THE UPJOHN COMPANY (US) 1994-01-19 EP disclosed
WO-1992017490-A1 PHOSPHORUS CONTAINING COMPOUNDS AS INHIBITORS OF RETROVIRUSES THE UPJOHN COMPANY (US) 1992-10-15 WO disclosed
EP-0497835-A1 METHOD FOR TREATING HIV AND OTHER RETROVIRUSES AND COMPOUNDS USEFUL THEREFOR THE UPJOHN COMPANY (US) 1992-08-12 EP disclosed
WO-1991006561-A1 METHOD FOR TREATING HIV AND OTHER RETROVIRUSES AND COMPOUNDS USEFUL THEREFOR THE UPJOHN COMPANY (US) 1991-05-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230348369-A1 NAMPT MODULATORS NAMPT, NNT, NAPRT SIGMAR1 2155/4885KDM5A 3669/4885PHF8 2908/4885
US-20120329830-A1 Amino Heteroaryl Compounds as Beta-Secretase Modulators and Methods of Use BACE1, BACE2, APP SIGMAR1 3065/4885KDM5A 2209/4885PHF8 4088/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.